Genetics of adrenal tumors

Minerva Endocrinologica

Volumn 34, Issue 2, 2009, Pages 107-121

  Opocher, G ^a,c   Schiavi, F ^a   Cicala, M V ^b,c   Patalano, A ^b,c   Mariniello, B ^b,c   Boaretto, F ^a   Zovato, S ^a   Pignataro, V ^a   Macino, B ^a   Negro, I ^b,c   Mantero, F ^b,c  

^a VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^b UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^c UNIVERSITY OF PADOVA   (Italy)

Author keywords

Adrenal gland; Genetics; Genomics; Neoplasms

Indexed keywords

CYCLIC AMP DEPENDENT PROTEIN KINASE 1; GUANINE NUCLEOTIDE BINDING PROTEIN; PROTEIN RET; SOMATOMEDIN B; VON HIPPEL LINDAU PROTEIN; WNT PROTEIN; TUMOR MARKER; TUMOR PROTEIN;

ADRENAL CANCER; ADRENAL CORTEX CARCINOMA; ADRENAL CORTEX TUMOR; ADRENAL MEDULLA; ADRENAL TUMOR; BECKWITH WIEDEMANN SYNDROME; CANCER GENETICS; CELL HYPOXIA; CHROMOSOME 11P; EMBRYOLOGY; ENDOCRINOLOGY; FAMILIAL CANCER; GENE; GENE MUTATION; GENETIC ANALYSIS; GENETIC SUSCEPTIBILITY; GENOMICS; GENOTYPE; HEREDITY; HUMAN; MULTIPLE ENDOCRINE NEOPLASIA; NEUROFIBROMATOSIS; PARAGANGLIOMA; PARAGANGLION; PARASYMPATHETIC GANGLION; PHEOCHROMOCYTOMA; REVIEW; SDHB GENE; SDHC GENE; SDHD GENE; SIGNAL TRANSDUCTION; SYMPATHETIC GANGLION; VON HIPPEL LINDAU DISEASE; GENETIC PREDISPOSITION; GENETICS; MUTATION; PATHOLOGY;

ADRENAL CORTEX NEOPLASMS; ADRENAL GLAND NEOPLASMS; ADRENOCORTICAL CARCINOMA; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; MUTATION; NEOPLASM PROTEINS; PARAGANGLIOMA; PHEOCHROMOCYTOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 70349773393     PISSN: 03911977     EISSN: 18271634     Source Type: Journal    
DOI: None     Document Type: Review

References (81)

1. Gudmundsson J, Sulem P, Gudbjartsson DF, Jonasson JG, Sigurdsson A, Bergthorsson JT et al. Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations. Nat Genet 2009 [Epub ahead of print].
2. Beuschlein F, Reinke M, et al. Clonal composition of human adrenocortical neoplasm. Cancer Research 1994;54:4927-32. (Pubitemid 24289423)
3. Hisada M, Garber JE, Fung CY, Fraumeni JF, Li FP. Multiple primary cancers in families with Li-Fraumeni syndrome. J Natl Cancer Inst 1998;90:606-11. (Pubitemid 28204804)
4. Caron de Fromentel C, Soussi T. TP53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 1992;4:1-15.
5. Varley JM, McGown G, Thorncroft M, James LA, Margison GP, Forster G et al. Are there low-penetrance TP53 alleles? Evidence from childhood adrenocortical tumors. Am J Hum Genet 1999;65:995-1006. (Pubitemid 30462956)
6. Ohgaki H, Kleihues P, Heitz PU. p53 mutations in sporadic adrenocortical tumors. Int J Cancer 1993;54:408-10.
7. Barzon L, Chilosi M, Fallo F, Martignoni G, Montagna L, Palu G et al. Molecular analysis of CDKN1C and TP53 in sporadic adrenal tumors. Eur J Endocrinol 2001;145:207-12. (Pubitemid 32707608)
8. Boulle N, LogiéÈ A, Gicquel C, Perm L, Le Bouc Y. Increased levels of insulin-like growth factor II (IGF-II) and IGF-binding protein-2 are associated with malignancy in sporadic adrenocortical tumors. J Clin Endocrinol Metab 1998;83:1713-20. (Pubitemid 28501047)
9. Ilvesmaki V, Kahri AI, Miettinen PJ, Voutilainen R. Insulin-like growth factors (IGFs) and their receptors in adrenal tumors: high IGF-II expression in functional adrenocortical carcinomas. J Clin Endocrinol Metab 1993;77:852-8. (Pubitemid 23298679)
10. de Fraipont F, El Atifi M, Cherradi N, Le Moigne G, Defaye G, Houlgatte R et al. Gene expression profiling of human adrenocortical tumors using cDNA microarrays identifies several candidate genes as markers of malignancy. J Clin Endocrinol Metab 2005;90:1819-29. (Pubitemid 40464057)
11. Matsuoka S, Edwards MC, Bai C, Parker S, Zhang P, Baldini A et al. P57kip2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev 1995;9:650-62.
12. Hertel NT, Carlsen N, Kerndrup G, Pedersen IL, Clausen N, Hahnemann JM et al. Late relapse of adrenocortical carcinoma in Beckwith-Wiedemann syndrome. Clinical, endocrinological and genetics aspects. Acta Paediatr 2003;92:439-43.
13. Bossis I, Stratakis CA. Minireview: Prkarla: normal and abnormal functions. Endocrinology 2004;145:5452-8. (Pubitemid 39564583)
14. Kirschner LS, Sandrini F, Monbo J, Lin JP, Carney JA, Stratakis CA. Genetic heterogeneity and spectrum of mutations of the PRKAR1a gene in patients with the Carney complex. Hum Mol Genet 2000;9:3037-46. (Pubitemid 32000777)
15. Carney JA, Gordon H, Carpenter PC, Shenoy BV, Go VL. The complex of myxomas, spotty pigmentation, and endocrine overactivity. Medicine (Baltimore) 1985;64:270-83. (Pubitemid 16247109)
16. Groussin L, Kirschner LS, Vincent-Dejean C, Perlemoine K, Jullian E, Delemer B et al. Molecular analysis of the cyclic AMP-dependent protein kinase a (PKA) regulatory subunit la (PRKAR1a) gene in patients with Carney complex and primary pigmented nodular adrenocortical disease (PPNAD) reveals novel mutations and clues for pathophysiology: Augmented PKA signaling is associated with adrenal tumorigenesis in PPNAD. Am J Hum Genet 2002;71:1433-42.
17. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM. Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 1991;325:1688-95.
18. Naylor EW, Gardner EJ. Clin Genet 1981;20:67-73.
19. Bläker H, Sutter C, Kadmon M, Otto HF, Von Knebel-Doeberitz M, Gebert J et al. Genes Chromosomes Cancer 2004;41:93-8.
20. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré AM et al. Cancer Res 2005;65:7622-7.
21. Gaujoux S, Tissier F, Groussin L, LibéÈ R, Ragazzon B, Launay P et al. J Clin Endocrinol Metab 2008;93:4135-40.
22. Kotoula V, Sozopoulos E, Litsiou H, Fanourakis G, Koletsa T, Voutsinas G et al. Endocr Relat Cancer 2009 [Epub ahead of print].
23. Nakamura M, Miki Y, Akahira JI, Morimoto R, Satoh F, Ishidoya S et al. Endocr Pathol 2009 [Epub ahead of print].
24. Maher ER, Eng C. The pressure rises: update on the genetics of Phaeochromocytoma. Hum Mol Genet 2002;11:2347-54. (Pubitemid 35174697)
25. Astuti D, Douglas F, Lennard TWJ, Agaliaganis I, Woodward ER, Evans DGR et al. Germline SDHD mutation in familial phaeochromocytoma. Lancet 2001;357:1181-2. (Pubitemid 32378695)
26. Astuti D, Latif F, Dallol A, Dahia PLM, Douglas F, George E et al. Mutations in the mitochondrial complex II subunit SDHB cause susceptibility to familial paraganglioma and pheochromocytoma. Am J Hum Genet 2001;69:49-54.
27. Neumann HPH, Bausch B, Mcwhinney SR, Bender BU, Gimm O, Franke G et al. Germ-line mutations in non-syndromic pheochromocytoma. N Engl J Med 2002;346:1459-66. (Pubitemid 34755714)
28. Mannelli M, Castellano M, Schiavi F, Filetti S, Giacchè M, Mori L et al.; the Italian Pheochromocytoma/Paraganglioma Network. Clinically guided genetic screening in a large cohort of Italian patients with pheochromocytornas and/or functional or non-functional paragangliomas. J Clin Endocrinol Metab 2009 [Epub ahead of print].
29. Kaelin WG Jr. Molecular basis of the VHL hereditary cancer syndrome. Nat Rev Cancer 2002;2:673-82.
30. Crossey PA, Foster K, Richards FM, Phipps ME, Latif F, Tory K et al. Molecular genetic investigations of the mechanism of tumourigenesis in von Hippel-Lindau disease: analysis of allele loss in VHL tumours. Hum Genet 1994;93:53-8. (Pubitemid 24016732)
31. Knudson AG Jr. Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A 1971;68:820-3.
32. Bender BU, Gutsche M, Glasker S, Muller B, Kirste G, Eng C et al. Differential genetic alterations in von Hippel-Lindau syndrome-associated and sporadic pheochromocytornas. J Clin Endocrinol Metab 2000;85:4568-74. (Pubitemid 32157635)
33. Lui WO, Chen J, Glasker S, Bender BU, Madura C, Khoo SK et al. Selective loss of chromosome 11 in pheochromocytornas associated with the VHL syndrome. Oncogene 2002;21:1117-22. (Pubitemid 34174524)
34. Kwok JB, Gardner E, Warner JP, Ponder BA, Mulligan LM. Structural analysis of the human ret proto-oncogene using exon trapping. Oncogene 1993;8:2575-82. (Pubitemid 23252389)
35. Myers SM, Eng C, Ponder BA, Mulligan LM. Characterization of RET proto-oncogene 3′ splicing variants and polyadenylation sites: a novel C-terminus for RET. Oncogene 1995;11:2039-45.
36. Le Hir H, Charlet-Berguerand N, Gimenez-Roqueplo A, Mannelli M, Plouin P, de Franciscis V et al. Relative expression of the RET9 and RET51 isoforms in human pheochromocytornas. Oncology 2000;58:311-8. (Pubitemid 30265341)
37. Le Hir H, Charlet-Berguerand N, de Franciscis V, Thermes C. 5′-End RET splicing: absence of variants in normal tissues and intron retention in pheochromocytornas. Oncology 2002;63:84-91.
38. Huang SC, Koch CA, Vortmeyer AO, Pack SD, Lichtenauer UD, Mannan P et al. Duplication of the mutant RET allele in trisomy 10 or loss of the wildtype allele in multiple endocrine neoplasia type 2-associated pheochromocytornas. Cancer Res 2000;60:6223-6.
39. Takahashi M, Cooper GM. RET transforming gene encodes a fusion protein homologous to tyrosine kinases. Mol Cell Biol 1987;7:1378-85. (Pubitemid 17045226)
40. Treanor JJ, Goodman L, de Sauvage F, Stone DM, Poulsen KT, Beck CD et al. Characterization of a multicomponent receptor for GDNF [see comments]. Nature 1996;382:80-3.
41. Trupp M, Arenas E, Fainzilber M, Nilsson AS, Sieber BA, Grigoriou M et al. Functional receptor for GDNF encoded by the c-RET proto-oncogene [see comments]. Nature 1996;381:785-8.
42. Durbec P, Marcos-Gutierrez CV, Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P et al. GDNF signalling through the Ret receptor tyrosine kinase [see comments]. Nature 1996;381:789-93.
43. Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson EM Jr et al. Neurturin, a relative of glial-cell-line-derived neurotrophic factor. Nature 1996;384:467-70.
44. Milbrandt J, de Sauvage FJ, Fahrner TJ, Baloh RH, Leitner ML, Tansey MG et al. Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 1998;20:245-53.
45. Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS et al. Artemin, a novel member of the GDNF ligand family, supports peripheral and central neurons and signals through the GFRalpha3-RET receptor complex. Neuron 1998;21:1291-302.
46. Bausch B, Borozdin W, Mautner VF, Hoffmann MM, Boehm D, Robledo M et al.; European-American Phaeochromocytoma Registry Study Group. Germline NFl mutational spectra and loss-of-heterozygosity analyses in patients with pheochromocytoma and neurofibromatosis type 1. J Clin Endocrinol Metab 2007;92:2784-92.
47. Hirawake H, Taniwaki M, Tamura A, Kojima S, Kita K. Cytochrome b in human complex II (succinate-ubiquinone oxidoreductase): cDNA cloning of the components in liver mitochondria and chromosome assignment of the genes for the large (SDHC) and small (SDHD) subunits to 1q21 and 11q23. Cytogenet Cell Genet 1997;79:132-8.
48. Gimm O, Armanios M, Dziema H, Neumann HP, Eng C. Somatic and occult germ-line mutations in SDHD, a mitochondrial complex II gene, in nonfamilial pheochromocytoma. Cancer Res 2000;60:6822-5.
49. Gimenez-Roqueplo AP, Favier J, Rustin P, Mourad JJ, Plouin PF, Corvol P et al. The R22X mutation of the SDHD gene in hereditary paraganglioma abolishes the enzymatic activity of complex II in the mitochondrial respiratory chain and activates the hypoxia pathway. Am J Hum Genet 2001;69:1186-97.
50. Leckschat S, Ream-Robinson D, Scheffler IE. The gene for the iron sulfur protein of succinate dehydrogenase (SDH-IP) maps to human chromosome 1p35-36.1. Somat Cell Mol Genet 1993;19:505-11.
51. Au HC, Ream-Robinson D, Bellew LA, Broomfield PL, Saghbini M, Scheffler IE. Structural organization of the gene encoding the human iron-sulfur subunit of succinate dehydrogenase. Gene 1995;159:249-53.
52. Elbehti-Green A, Au HC, Mascarello JT, Ream-Robinson D, Scheffler IE. Characterization of the human SDHC gene encoding of the integral membrane proteins of succinate-quinone oxidoreductase in mitochondria. Gene 1998;213:133-40.
53. Niemann S, Muller U. Mutations in SDHC cause autosomal dominant paraganglioma, type 3. Nat Genet 2000;26:268-70.
54. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47. Review.
55. Pugh CW, Ratcliffe PJ. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis. Semin Cancer Biol 2003;13:83-9.
56. You MJ, Castrillon DH, Bastian BC, O'Hagan RC, Bosenberg MW, Parsons R et al. Genetic analysis of Pten and Ink4a/Arf interactions in the suppression of tumorigenesis in mice. Proc Natl Acad Sci U S A 2002;99:1455-60.
57. Chen C, Pore N, Behrooz A, Ismail-Beigi F, Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J Biol Chem 2001;276:9519-25.
58. Chen F, Kishida T, Yao M, Hustad T, Glavac D, Dean M et al. Germline mutations in the von Hippel-Lindau disease tumor suppressor gene: correlations with phenotype. Hum Mutat 1995;5:66-75.
59. Neumann HPH, Berger DP, Sigmund G, Blum U, Schmidt D, Parmer RJ et al. Pheochromocytornas, multiple endocrine neoplasia type 2, and von Hippel-Lindau disease. New Eng J Med 1993;329:1531-8.
60. Zbar B, Kishida T, Chen F, Schmidt L, Maher ER, Richards FM et al. Germline mutations in the Von Hippel-Lindau disease (VHL) gene in families from North America, Europe, and Japan. Hum Mutat 1996;8:348-57.
61. Crossey PA, Richards FM, Foster K, Green JS, Prowse A, Latif F et al. Identification of intragenic mutations in the von Hippel-Lindau disease tumour suppressor gene and correlation with disease phenotype. Hum Molec Genet 1994;3:1303-8. (Pubitemid 124000498)
62. Chen F, Slife L, Kishida T, Mulvihill J, Tisherman SE, Zbar B. Genotype-phenotype correlation in von Hippel-Lindau disease: identification of a mutation associated with VHL type 2A. J Med Genet 1996;33:716-7. (Pubitemid 26270937)
63. Bender BU, Altehofer C, Januszewicz A, Gartner R, Schmidt H, Hoffmann MM et al. Functioning thoracic paraganglioma: association with Von Hippel-Lindau syndrome. J Clin Endocr Metab 1997;82:3356-60. (Pubitemid 27419086)
64. Hes FJ, Hoppener JW, Lips CJ. Clinical review 155: pheochromocytoma in Von Hippel-Lindau disease. J Clin Endocrinol Metab 2003;88:969-74.
65. Eisenhofer G, Walther MM, Huynh T-T, Li S-T, Bornstein SR, Vortmeyer A et al. Pheochromocytornas in von Hippel-Lindau syndrome and multiple endocrine neoplasia type 2 display distinct biochemical and clinical phenotypes. J Clin Endocr Metab 2001;86:1999-2008. (Pubitemid 32472911)
66. Jacks T, Shih TS, Schmitt EM, Bronson RT, Bernards A, Weinberg RA. Tumour predisposition in mice heterozygous for a targeted mutation in Nf1. Nat Genet 1994;7:353-61 (Pubitemid 24204410)
67. Walther MM, Herring J, Enquist E, Reiser HR, Linehan WM. von Recklinghausen's disease and pheochromocytornas. J Urol 1999;162:1582-6.
68. Zoller ME, Rembeck B, Oden A, Samuelsson M, Angervall L. Malignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish population. Cancer 1997;79:2125-31. (Pubitemid 27227376)
69. Neumann HP, Pawlu C, Peczkowska M, Bausch B, McWhinney SR, Muresan M et al.; European-American Paraganglioma Study Group. Distinct clinical features of paraganglioma syndromes associated with SDHB and SDHD gene mutations. JAMA 2004;292:943-51
70. Baysal BE. Hereditary paraganglioma targets diverse paraganglia. J Med Genet 2002;39:617-22.
71. Zak FG, Lawson W. Anatomy and topography. In: Zak FG, Lawson W, editors. The paraganglionic chemoreceptor system. Berlin: Springer-Verlag; 1982. p. 15-49
72. Lack EE. Anatomy and physiology of peripheral arterial chemoreceptors. In: Lack EE, editor. Pathology of adrenal and extra-adrenal paraganglia. Philadelphia, PA: W.B. Saunders; 1994. p. 1-14.
73. Gujrathi CS, Donald PJ. Current trends in the diagnosis and management of head and neck paragangliomas. Curr Opin Otolaryngol Head Neck Surg 2005;13:339-42.
74. Grufferman S, Gillman MW, Pasternak LR, Peterson CL, Young WG Jr. Familial carotid body tumors: case report and epidemiologic review. Cancer 1980;46:2116-22. Review. (Pubitemid 10025492)
75. rd et al. Proportion of heritable paraganglioma cases and associated clinical characteristics. Laryngoscope 2001;111:1822-7.
76. van der Mey AG, Maaswinkel-Mooy PD, Cornelisse CJ, Schmidt PH, van de Kamp JJ. Genomic imprinting in hereditary glomus tumours: evidence for new genetic theory. Lancet 1989;2:1291-4. Review.
77. Gimm O, Koch CA, Januszewicz A, Opocher G, Neumann HP. The genetic basis of pheochromocytoma. Front Horm Res 2004;31:45-60. Review.
78. Hederstedt L. Structural biology. Complex II is complex too. Science 2003;299:671-2.
79. Maxwell PH. A common pathway for genetic events leading to pheochromocytoma. Cancer Cell 2005;8:91-3.
80. Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP et al. Neuronal apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromocytoma genes: developmental culling and cancer. Cancer Cell 2005;8:155-67.
81. Gottlieb E, Tomlinson IP. Mitochondrial tumour suppressors: a genetic and biochemical update. Nat Rev Cancer 2005;5:857-66. Review.